This paper aimed to evaluate the expression of REGg and characterize its clinical significance in papillary thyroid carcinoma (PTC).
Background
Papillary thyroid carcinoma (PTC) is a well-differentiated thyroid cancer, accounting for more than 80% of all thyroid tumors [1] . Additionally, PTC encompasses several subtypes, such as the follicular variant (FV), which is characterized by a follicular pattern of growth and can be easily confused with follicular carcinomas and follicular adenomas [2] . Lymph node metastases in PTC have been demonstrated as an independent risk factor for regional recurrence and are correlated with a higher rate of distant metastasis [3] . The current treatment for PTC involves thyroid-stimulating hormone suppression therapy, surgery, and radioactive iodine (RAI) therapy [4] . However, the incidence of PTC is increasing and those patients with distant metastasis are refractory to RAI. Hence, there is an urgent need to explore new indicators for diagnosis and prognosis of PTC.
REGgamma (REGg), also known as PA28g, PSME3, 11sg, or Ki antigen, was first found in the serum of systemic lupus erythematosus patients as a nuclear protein targeted by autoantibodies [5] . Although the biological roles of REGg are not fully understood, the proteasome activator REGg has been reported to bind and activate the 20S proteasome to stimulate the proteolytic functions of the proteasome independent of ubiquitination and ATP [6] . Mounting evidence demonstrates that REGg is involved in cancer progression [5] . REGg is reported to be over-expressed in many kinds of cancers, such as laryngeal carcinoma, thyroid cancer, breast cancer, and gastric cancer [7] [8] [9] [10] . Fan et al. showed that a high level of REGg expression was positively associated with poor clinical outcomes and prognosis of patients with breast cancer [8] . Recently, it was reported that REGg plays a significant role in cell proliferation, cell cycle, and invasion of poorly differentiated thyroid carcinoma cells [7] . However, the clinical significance of REGg expression in PTC has not been systematically studied.
In the present study, we retrospectively investigated the REGg expression levels in thyroid tissues from patients with PTC with or without lymph node metastases and normal controls. Correlations between the expression levels of REGg and clinicopathological parameters and prognosis were analyzed statistically.
Material and Methods

Human subjects
In total, 54 PTC patients with or without lymph node metastases who underwent total or subtotal thyroidectomy and neck node dissection for PTC from February 2009 to September 2011 at Xinhua Hospital, Shanghai Jiao tong University School of Medicine (Shanghai, China) were reviewed retrospectively. These patients were randomly and consecutively selected and they had no other malignant tumors or other thyroid disease. Thyroid specimens from these 54 patients were collected and established by post-operation pathology. Clinicopathological characteristics for these patients were collected and analyzed, including age, sex, tumor size, nodal status, and tumor multiplicity. Clinical staging was undertaken based on surgical and preoperative examination. Normal thyroid tissues as controls were also obtained from 13 volunteers without history of thyroid cancer, using ultrasound-guided fine-needle aspiration. Study approval was obtained from the Institutional Review Board of Shanghai Xinhua Hospital, Shanghai Jiao tong University School of Medicine (Shanghai, China).
Immunohistochemical evaluation of REGg expression
Immunohistochemical (IHC) analysis was conducted to analyze the protein level of REGg in PTC tissues and normal thyroid tissues. Briefly, the tissues were fixed, dehydrated, embedded in paraffin, and cut into 4-μm-thick tissue sections. Then, the sections were subjected to antigen retrieval with 0.01 M citrate buffer solution at pH 6.0 for 30 min in a 100°C water bath. After cooling to room temperature, the sections were treated with 3% H 2 O 2 (in absolute methanol) for 10 min to block endogenous peroxidase activity. Subsequently, the sections were incubated in serum albumin (Histostain™-Plus DAB kit) at room temperature for 10 min to block non-specific staining. Pretreated tissue sections were incubated overnight at 4°C with the specific primary antibodies (rabbit polyclonal anti-REGg antibody, 1: 300). Slides were then incubated with biotinylated anti-rabbit IgG (DAB kit) (Miaotong Shanghai biological technology co., LTD) for 10 min. After incubation with secondary horseradish peroxidase (HRP) antibody for 10 minutes, Mayer's hematoxylin was used to counterstain sections.
Expression of REGg was scored by assigning proportion and intensity scores, according to an immuno-reactive score (IRS) system described by Remmele and Stegner [11] . In brief, the intensity score represents the staining intensity (SI) as follows: 0=no staining, 1=faint staining, 2=moderate staining, 3=strong staining. A proportion score represented the approximate percentage of positive cells as follows: 0=no positive cells, 1=less than 5%, 2=6-10%, 3=11-50%, 4=50-100%. The final IRS, ranging from 0 to 12, was calculated by multiplying SI and PP. In this study, tumors with final IRS >5 were evaluated as positive; while those cases assigned an IRS £5 (negative or weak expression) were evaluated as negative. The staining intensity and the proportion of positive cells were calculated by 2 independent blinded observers using an ordinal scale [12] .
Statistical analysis
Statistical analyses were performed with the use of SAS version 3.1 statistical software package (SAS Institute, Cary, NC). Student's t-test was used for and comparing the means in continuous variables. Fisher's exact test or Pearson's chi-square test was used for the measurement of statistical differences in categorical variables. We performed binary logistic regression modeling to identify predictors of lymph node metastasis.
Age, T-stage, and tumor multiplicity were included as covariates in the regression model. Data are presented as mean ± standard deviation (SD). All statistical tests were two-sided, with a 0.05 level of significance.
Results
Clinical pathological features in PTC patients
Total or near total thyroidectomy was performed for 52 patients (96.3%). The other 2 patients underwent lobectomy. Neck dissection for the central compartment was performed in 26 patients (48.1%), modified radical neck dissection including central neck dissection was performed in 10 patients (18.5%), and functional neck dissection was performed in 18 patients (33.4%). Tumor size, T-stage, and lymph nodes metastasis were established by post-surgical pathology. The clinicopathological characteristics of these 54 patients with PTC are listed in Figure 1) .
The relationship between REGg and clinicopathological findings
All the normal thyroid tissues were REGg-negative. There were 29 REGg-positive cases in T1-T2 (29/42, 69.0%) and 12 cases were in T3-T4 (12/12, 100% 
Discussion
In this study, positive REGg staining was identified in most (41/54) patients with PTC. In addition, positive REGg expression was more frequently found in PTC patients with lymph node metastasis (32/35, 91.4%). Moreover, REGg expression level was associated with lymph node metastasis and T-stage. REGg expression was a significant independent predictor of lymph node metastasis of PTC patients.
REGg is abnormally over-expressed in thyroid cancer, especially in its growth-accelerated cells, indicating that REGg may play a role in the regulatory system for the cell cycle [13] . Zhang et al. demonstrated that the down-regulation of REGg arrested the cell cycle, inhibited cell proliferation, and also restricted invasion of poorly differentiated thyroid carcinoma cells [7] . Moreover, studies have shown that cell proliferation and cell cycle progression were inhibited in REGg-knockdown Drosophila, REGg-knockout mice cells, mouse embryonic fibroblasts, breast carcinoma cells, and SW579 cells [7, 14, 15] . It was shown that REGg promotes human breast ductal epithelial cells (HBL-100) to transition from G1 into S phase [16] , which may trigger breast neoplasms [17, 18] . Tomohisa et al. observed a significant correlation between proliferating cell nuclear antigen (PCNA) and REGg expression [13] . As a key transition factor in cell cycle progression, PCNA is over-expressed in PTC [19] . In addition, REGg has been demonstrated to modulate the activity of p53 and p21 proteins [20, 21] . The ability of P53 to stimulate apoptosis and cell cycle arrest and strongly suppress oncogenesis is well documented [22] . p21 occupies a critical position in cell cycle regulation in many tissues [23] . Evans et al. reported on the relationship between REGg, and p21 and p53 in human PTC tissues [24] . In the present study, we found that REGg was over-expressed in PTC tissue specimens from most PTC patients (41/54, 75.9%). We assumed a pivotal role of REGg in the PTC progression through affecting cell cycle and proliferation. On the other hand, most positive REGg cases showed nuclear staining in this study, which was consistent with the finding of Okamura et al., showing that REGg was localized within the nucleus of thyroid cancer cells [13] .
The presence and the location of regional lymph node metastasis are correlated with a high risk of recurrence and distant metastases, and can affect the prognosis of PTC [25, 26] . In this study, we found that REGg expression was associated with T-stage and lymph node metastasis. Using binary logistic regression analysis, we sowed that REGg is a significant independent predictor for lymph node metastasis. These findings indicate that the REGg expression level may be a significant predictor factor of lymph node metastasis and T-stage in PTC patients. However, this conclusion needs validation in the future.
Our study had some limitations, mainly due to the retrospective design and the limited number of cases. However, to the best of our knowledge, the present study is the first investigation of the relationship between REGg and pathological findings in PTC patients. Although the current study indicated that REGg may be a predictor for lymph node metastasis and T-stage, more definitive evidence is required. Concerning the suggestion that REGg may represent a therapeutic target in some tumors [6] , further studies to uncover the role of the REGg in PTC are required.
Conclusions
In conclusion, our results are the first to indicate that REGg expression may be associated with lymph node metastasis and T-stage in PTC patients. The expression of REGg has no direct correlation with the sex, age, tumor size, or tumor multiplicity of the patients, but high expression of REGg was positively correlated with T-stage and lymph node metastasis, suggesting that REGg is a prognostic marker of T-stage and lymph node metastasis and is also a therapeutic target for PTC.
